Title: Prevalence of Co morbidities among patients having Multi Drug Resistant Tuberculosis: A Retrospective Analysis
Authors: Dr Kamendra Singh Pawar, Dr Ramakant Dixit
DOI: https://dx.doi.org/10.18535/jmscr/v6i4.168
Abstract
The comorbid conditions may have both impact as risk factor for developing MDR TB and they may influence the treatment outcomes as well. This study was planned with an objective of determining the prevalence of co morbid conditions associated with MDR-TB at the time of treatment initiation at Drug Resistant Tuberculosis Centre, Ajmer (Rajasthan), India. Data was extracted by reviewing of medical records of MDR-TB patients maintained at DR-TB centre retrospectively. Data of 127 patients were found eligible for study. There were 101 (79.5%) males and 26(20.4%) females with mean age of study group was 38.6 years (with C.I.(95%) of mean±2.27). Mean pre-treatment BMI was 15.81 Kg/m2 (C.I (95%) of mean was ±0.40). Among these 127 patients, comorbid conditions were present in 51 (40.1%) patients. Among patients with comorbidities, majority of patients had single comorbid illness (n=43, 84.3%) while 8 (15.6%) patients were having dual comorbidities. Among single comorbid states, COPD was found most common (n=16, 31.3%). In conclusion, great proportion of patient with MDR TB in our study were found to have comorbid conditions. Proper identifications and management of such concurrent medical conditions is vital as they may affect outcome of treatment which itself is challenging.
Keywords: MDR-TB, Comorbid conditions, Outcome.
References
- Central TB Division. Revised National Tuberculosis Control Programme: Guidelines on Programmatic Management of Drug Resistant TB (PMDT) in India (May 2012).Directorate General of Health Services, Ministry of Health and Family Welfare, New Delhi, Government of India. http://www.tbcindia.nic.in/showfile.php?lid=3155
- Central TB Division. Directorate General of Health Services, Ministry of Health and Family Welfare, New Delhi, Government of India. INDIA TB REPORT 2018. Revised National TB Control Programme: Annual Status Report. tbcindia.gov.in
- Samuels JP, Sood A, Campbell JR, Ahmad Khan F, Johnston JC. Comorbidities and treatment outcomes in multidrug resistant tuberculosis: a systematic review and meta-analysis. Sci Rep. 2018 Mar 21;8(1):4980. doi: 10.1038/s41598-018-23344-z.
- Dhingra VK, Rajpal S, Mittal A, Hanif M. Outcome of multi-drug resistant tuberculosis cases treated by individualized regimens at a tertiary level clinic. Indian J Tuberc. 2008;55:15-21.
- Yew WW, Chan CK, Chau CH, Tam CM, Leung CC, Wong PC, et al. Outcomes of patients with multidrug- resistant pulmonary tuberculosis treated with ofloxacin/ levofl oxacin-containing regimens. Chest 2000; 117:744–51.
- Joseph P, Desai VB, Mohan NS, Fredrick JS, Ramachandran R, Raman B, et al. Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India. Indian J Med Res. 2011;133:529-34.
- Tegegne BS, Habtewold TD, Mengesha MM, Burgerhof JGM. Association between diabetes mellitus and multi-drug-resistant tuberculosis: a protocol for a systematic review and meta-analysis. Syst Rev. 2017; 6: 6. doi: 1186/s13643-017-0407-9.
- Akshata JS, Chakrabarthy A. Management of multidrug resistant tuberculosis (MDR-TB) – Monitoring is the key to successful outcome. Egypt J Chest Dis Tuberc. 2016;65:447-50.
- Mpagama SG, Heysell SK, Ndusilo ND, Kumburu HH, Lekule IA, Kisonga RM, et al. Diagnosis and interim treatment outcomes from the first cohort of multidrug-resistant tuberculosis patients in Tanzania. PLoS One. 2013;8:e62034. doi: 10.1371/journal.pone.0062034.
- Snider DE Jr. The relationship between tuberculosis and silicosis. Am Rev Respir Dis. 1978;118:455-60.